Stopped: Study Closure
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Natural history of CHB: Characteristics of CHB infection
Timeframe: Up to 10 years
Natural history of CHB: Participant demographics
Timeframe: Up to 10 years
Natural history of CHB: Treatment use
Timeframe: Up to 10 years
Natural history of CHB: Treatment response
Timeframe: Up to 10 years
Time point of clinical response
Timeframe: Every 6 months for 10 years
Natural history of CHB: Disease progression
Timeframe: Up to 10 years
Adverse event frequency and severity
Timeframe: Up to 10 years